Related references
Note: Only part of the references are listed.
Review
Health Care Sciences & Services
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
Mauro Ceccanti et al.
Summary: This article provides a review and opinion on the pharmacological and nonpharmacological treatments for neonatal abstinence syndrome (NAS). The prevalence of NAS has been increasing, and the management involves a combination of pharmacological and nonpharmacological therapies. Opioid therapy is the preferred pharmacological treatment, and genetic polymorphisms may affect the length of stay and the need for pharmacotherapy. The authors suggest that genetic assessment and DNA-directed precision therapy should be considered in the future.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Share Paper
